Cargando…

Novel Therapeutic Target Critical for SARS-CoV-2 Infectivity and Induction of the Cytokine Release Syndrome

We discovered a novel therapeutic target critical for SARS-CoV-2, cellular infectivity and the induction of the cytokine release syndrome. Here, we show that the mammalian enzyme neuraminidase-1 (Neu-1) is part of a highly conserved signaling platform that regulates the dimerization and activation o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harless, William W., Lewis, Beth, Qorri, Bessi, Abdulkhalek, Samar, Szewczuk, Myron R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177205/ https://www.ncbi.nlm.nih.gov/pubmed/37174732 http://dx.doi.org/10.3390/cells12091332

Ejemplares similares

Next Generation of Cancer Drug Repurposing: Therapeutic Combination of Aspirin and Oseltamivir Phosphate Potentiates Gemcitabine to Disable Key Survival Pathways Critical for Pancreatic Cancer Progression
por: Qorri, Bessi, et al.
Publicado: (2022)

Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells
por: Qorri, Bessi, et al.
Publicado: (2020)

Repositioning of Old Drugs for Novel Cancer Therapies: Continuous Therapeutic Perfusion of Aspirin and Oseltamivir Phosphate with Gemcitabine Treatment Disables Tumor Progression, Chemoresistance, and Metastases
por: Qorri, Bessi, et al.
Publicado: (2022)

Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity
por: Sambi, Manpreet, et al.
Publicado: (2017)

A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer
por: Sambi, Manpreet, et al.
Publicado: (2020)

Recent advances in “smart” delivery systems for extended drug release in cancer therapy
por: Kalaydina, Regina-Veronicka, et al.
Publicado: (2018)

The crucial role of primary care providers in the long-term follow-up of adult survivors of childhood cancer
por: Jain, Justin, et al.
Publicado: (2019)

Non-Nutritive Sweeteners and Their Implications on the Development of Metabolic Syndrome
por: Liauchonak, Iryna, et al.
Publicado: (2019)

Therapeutic potential of medicinal marijuana: an educational primer for health care professionals
por: Mouhamed, Yara, et al.
Publicado: (2018)

Agonist-Biased Signaling via Matrix Metalloproteinase-9 Promotes Extracellular Matrix Remodeling
por: Qorri, Bessi, et al.
Publicado: (2018)

Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance
por: O’Shea, Leah K, et al.
Publicado: (2014)

Therapeutic designed poly (lactic-co-glycolic acid) cylindrical oseltamivir phosphate-loaded implants impede tumor neovascularization, growth and metastasis in mouse model of human pancreatic carcinoma
por: Hrynyk, Michael, et al.
Publicado: (2015)

The Biased G-Protein-Coupled Receptor Agonism Bridges the Gap between the Insulin Receptor and the Metabolic Syndrome
por: Liauchonak, Iryna, et al.
Publicado: (2018)

3D Multicellular Stem-Like Human Breast Tumor Spheroids Enhance Tumorigenicity of Orthotopic Xenografts in Athymic Nude Rat Model
por: Mokhtari, Reza Bayat, et al.
Publicado: (2021)

The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy
por: Mokhtari, Reza Bayat, et al.
Publicado: (2021)

Oseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinoma
por: Haxho, Fiona, et al.
Publicado: (2014)

Contemporaneous SARS-CoV-2-Neutralizing Antibodies Mediated by N-glycan Shields
por: Baghaie, Leili, et al.
Publicado: (2023)

Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis
por: Mokhtari, Reza Bayat, et al.
Publicado: (2021)

Correction: Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis
por: Mokhtari, Reza Bayat, et al.
Publicado: (2022)

Machine learning identifies molecular regulators and therapeutics for targeting SARS‐CoV2‐induced cytokine release
por: Chan, Marina, et al.
Publicado: (2021)

Understanding the andromeda strain – The role of cytokine release, coagulopathy and antithrombin III in SARS-CoV2 critical illness
por: Mir, Nabiel, et al.
Publicado: (2021)

Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2
por: Corominas, Hèctor, et al.
Publicado: (2021)

Transcriptional factor snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma
por: Abdulkhalek, Samar, et al.
Publicado: (2014)

Cytokines and Chemokines in SARS-CoV-2 Infections—Therapeutic Strategies Targeting Cytokine Storm
por: Pum, Alexandra, et al.
Publicado: (2021)

Revisiting perioperative chemotherapy: the critical importance of targeting residual cancer prior to wound healing
por: Harless, William W
Publicado: (2009)

Neuraminidase-1: A novel therapeutic target in multistage tumorigenesis
por: Haxho, Fiona, et al.
Publicado: (2016)

Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2
por: Wang, Long G, et al.
Publicado: (2022)

Role of Therapeutic Plasmapheresis in SARS-CoV-2 Induced Cytokine Release Syndrome: A Retrospective Cohort Study on COVID-19 Patients
por: Jamil, Zubia, et al.
Publicado: (2022)

Oseltamivir phosphate released from injectable Pickering emulsions over an extended term disables human pancreatic cancer cell survival
por: Wood, Kurt, et al.
Publicado: (2018)

The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines
por: Luban, Jeremy, et al.
Publicado: (2021)

Cytokine Profiles as Potential Prognostic and Therapeutic Markers in SARS-CoV-2-Induced ARDS
por: Salton, Francesco, et al.
Publicado: (2022)

In Vitro SARS-CoV-2 Infection of Microvascular Endothelial Cells: Effect on Pro-Inflammatory Cytokine and Chemokine Release
por: Dolci, Maria, et al.
Publicado: (2022)

Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia
por: Hegazy, Ahmed N., et al.
Publicado: (2022)

Cytokine storm induced by SARS-CoV-2
por: Song, Peipei, et al.
Publicado: (2020)

Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
por: Pelaia, Corrado, et al.
Publicado: (2021)

Unconventional secretion of unglycosylated ORF8 is critical for the cytokine storm during SARS-CoV-2 infection
por: Lin, Xiaoyuan, et al.
Publicado: (2023)

Early treatment to prevent progression of SARS-CoV-2 infection
por: Cohen, Myron S
Publicado: (2022)

TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines
por: Zheng, Min, et al.
Publicado: (2021)

GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro
por: Hong, Kyung Soo, et al.
Publicado: (2020)

SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release
por: Junqueira, Caroline, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dkkr0l0l1i427ajr5sq4eblcrf